Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07596030 · ClinicalTrials.gov registry record · NA

Self-applied taVNS for CIPN

A NA study, sponsored by University of Miami.

Recruiting
Registry status
NA
Development phase
36
Enrollment target

NCT07596030 is a NA study that is actively recruiting participants, run by University of Miami. The registered enrollment target is 36 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07596030, a NA study, is actively recruiting participants, sponsored by University of Miami.

RECRUITING
Registry status
NA
Development phase
36 participants
Enrollment target

Study Summary

The purpose of this study is to determine the feasibility of using a portable device at home to self-administer transcutaneous auricular vagus nerve stimulation (taVNS). This handheld device has two small electrodes that are placed on specific areas of the outer ear. This device delivers a mild electrical stimulation to the vagus nerve through the ear. This study will explore how taVNS may affect symptoms of chemotherapy-induced peripheral neuropathy (CIPN). Participants will be assigned to one of two cohorts based on the presence of chemotherapy-induced peripheral neuropathy (CIPN). Participants with CIPN will be placed in the intervention cohort (n=24) and will complete a 2-week trial of daily self-applied taVNS. Participants without CIPN will be placed in the registry cohort (n=12) and will complete study measurements without receiving the intervention. The registry cohort will not receive the taVNS intervention but will undergo identical physiological assessments at baseline and at a 2 week follow up to control for testing effects and biological variability.

Interventions

  • DEVICE Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2026-06-02
Est. Completion 2027-07
Phase NA

Sponsor

University of Miami

721 total trials

What the Registry Record Tells You About NCT07596030

The ClinicalTrials.gov registry entry for NCT07596030 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) is the first listed.

NCT07596030 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07596030 about?

NCT07596030 is a clinical study titled "Self-applied taVNS for CIPN". The purpose of this study is to determine the feasibility of using a portable device at home to self-administer transcutaneous auricular vagus nerve stimulation (taVNS). This handheld device has two small electrodes that are placed on specific areas of the outer ear. This device delivers a mild elec...

What is the current status of trial NCT07596030?

This trial is currently recruiting. It is a NA study. The enrollment target is 36 participants. The study started on 2026-06-02. Estimated completion is 2027-07.

What interventions are being tested in trial NCT07596030?

The interventions under investigation include: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) (DEVICE).

Who is sponsoring clinical trial NCT07596030?

This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.